NICE’s Plans Could Delay Availability of Drugs on the NHS in England

The National Institute for Health and Care Excellence (NICE) plans to delay the introduction of new drugs that cost NHS England more than £20 million a year are likely to be enforced next month, a NICE announcement has revealed.

Sarah Woolnough, Cancer Research UK’s executive director of policy and information, disagrees with the plans and has said:

“If NICE thinks a cancer treatment is clinically effective and represents value for money, then patients should receive it without delay,”

“A system that could add up to a three year delay before patients can access treatments deemed clinically and cost effective is unacceptable,” said Woolnough. “Cancer patients may lose their lives whilst they wait.”

There are concerns that the additional barrier will disproportionately affect diseases with large numbers of patients, such as breast and lung cancer.

To read more about this, on the Cancer Research UK website, please click here.

Tagged with

Published on 17. March 2017 in News UK